Patents Assigned to Pharmos Corporation
  • Patent number: 9422235
    Abstract: The invention provides sulfonamide compounds of formula (I) as defined herein, pharmaceutical compositions containing the same and methods of treatment using such compounds and pharmaceutical compositions. These compounds have a common wide range of beneficial therapeutic indications, in particular as analgesic and anti-inflammatory agents.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: August 23, 2016
    Assignee: Pharmos Corporation
    Inventors: Avihai Yacovan, Iris Alroy, Alexander Aizikovich, Sima Mirilashvili, Flavio Grynszpan
  • Patent number: 9408852
    Abstract: Enantiomerically-pure (S)-tofisopam is administered to lower serum uric acid levels in a mammal.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: August 9, 2016
    Assignee: PHARMOS CORPORATION
    Inventors: Judi Gidner, Karen Raudibaugh, Brian Speicher
  • Publication number: 20130045966
    Abstract: Enantiomerically-pure (S)-tofisopam is administered to lower serum uric acid levels in a mammal.
    Type: Application
    Filed: July 26, 2012
    Publication date: February 21, 2013
    Applicant: Pharmos Corporation
    Inventors: Judi Gidner, Karen Raudibaugh, Brian Speicher
  • Publication number: 20090068143
    Abstract: The present invention relates to orally effective ligands of the peripheral cannabinoid receptor CB2, especially (+)-?-pinene derivatives, and to pharmaceutical compositions thereof, which are useful for prevention, alleviation or treatment of autoimmune neurodegenerative disorders, in particular multiple sclerosis and associated symptoms. Methods of the invention are useful when the active ingredient is administered alone or in combination with existing therapeutic modalities. The compositions are administered by oral route.
    Type: Application
    Filed: February 24, 2005
    Publication date: March 12, 2009
    Applicant: PHARMOS CORPORATION
    Inventors: Avihai Yacovan, Avi Bar-Joseph, Sigal Meilin, Shimon Amselem
  • Publication number: 20070213369
    Abstract: Novel non-psychotropic cannabinoids are disclosed and pharmaceutical compositions comprising these novel compounds are described for preventing neurotoxicity, neuroinflammation, immune or inflammatory disorders comprising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of ?6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to acute injuries to the central nervous system, including mechanical trauma, compromised or reduced blood supply as may occur in cardiac arrest or stroke, or poisonings. They are also effective in the treatment of certain inflammatory disorders and chronic degenerative diseases characterized by neuronal loss and chronic pain including neuropathic pain.
    Type: Application
    Filed: May 14, 2007
    Publication date: September 13, 2007
    Applicant: Pharmos Corporation
    Inventors: Aaron Garzon, George Fink
  • Patent number: 7235584
    Abstract: Novel non-psychotropic cannabinoids are disclosed and pharmaceutical compositions comprising these novel compounds are described for preventing neurotoxicity, neuroinflammation, immune or inflammatory disorders comprising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of ?6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to acute injuries to the central nervous system, including mechanical trauma, compromised or reduced blood supply as may occur in cardiac arrest or stroke, or poisonings. They are also effective in the treatment of certain inflammatory disorders and chronic degenerative diseases characterized by neuronal loss and chronic pain including neuropathic pain.
    Type: Grant
    Filed: June 25, 2003
    Date of Patent: June 26, 2007
    Assignee: Pharmos Corporation
    Inventors: Aaron Garzon, George Fink
  • Patent number: 6610737
    Abstract: Novel non-psychotropic cannabinoids are disclosed and pharmaceutical compositions comprising these novel compounds are described for preventing neurotoxicity, neuroinflammation, immune or inflammatory disorders comprising as active ingredient the stereospecific (+) enantiomer, having (3S,4S) configuration of &Dgr;6 tetrahydrocannabinol type compounds. The compositions are particularly effective in alleviating and even preventing neurotoxicity due to acute injuries to the central nervous system, including mechanical trauma, compromised or reduced blood supply as may occur in cardiac arrest or stroke, or poisonings. They are also effective in the treatment of certain inflammatory disorders and chronic degenerative diseases characterized by neuronal loss and chronic pain including neuropathic pain.
    Type: Grant
    Filed: November 26, 2002
    Date of Patent: August 26, 2003
    Assignee: Pharmos Corporation
    Inventors: Aaron Garzon, George Fink
  • Patent number: 6387955
    Abstract: The present invention discloses the use of permanently charged steroid agonists or antagonists as potent anti-angiogenic compositions comprising as an active ingredient a compound of the general formulae I, II or III: wherein DRUG is any steroid agonist or antagonist, a mixed agonist-antagonist, or a partial agonist and the substituents are as defined in the specification.
    Type: Grant
    Filed: May 3, 2000
    Date of Patent: May 14, 2002
    Assignee: Pharmos Corporation
    Inventors: Anat Biegon, Marcus E. Brewster
  • Patent number: 6083990
    Abstract: The present invention discloses the use of permanently charged steroid agonists or antagonists as potent anti-angiogenic compositions comprising as an active ingredient a compound of the general formulae I, II or III: ##STR1## wherein DRUG is any steroid agonist or antagonist, a mixed agonist-antagonist, or a partial agonist and the substituents are as defined in the specification.
    Type: Grant
    Filed: April 2, 1997
    Date of Patent: July 4, 2000
    Assignee: Pharmos Corporation
    Inventors: Anat Biegon, Marcus E. Brewster
  • Patent number: 5993846
    Abstract: The invention relates to novel methods for making oil-in-water emulsions having mucoadhesive properties which are primarily intended for administration of biologically active compounds to mucosal surfaces. The emulsion has an aqueous continuous phase and a plurality of submicron particles having an average particle diameter of from 10 nm to 600 nm, with the particles having a hydrophobic phase of a fat or oil which forms a hydrophobic core that is surrounded by a surfactant layer. The emulsion further includes a mucoadhesive polymer which is a polymer or copolymer of acrylic acid or methacrylic acid, a poly (methyl vinyl ether/maleic anhydride) copolymer, pectin, alginic acid, hyaluronic acid, chitosan, gum tragacanth, karaya gum or carboxymethylcellulose surrounding the hydrophobic one. A biologically active compound may also be included, if desired.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: November 30, 1999
    Assignee: Pharmos Corporation
    Inventors: Doron Friedman, Joseph Schwarz, Shimon Amselem
  • Patent number: 5961970
    Abstract: A vaccine adjuvant composition of an oil-in-water submicron emulsion that has about 0.5 to 50% of a first component of an oil, about 0.1 to 10% of a second component of an emulsifier, about 0.05 to 5% of a nonionic surfactant, about 0.00001 to 1% of an immunogen, and an aqueous continuous phase. This submicron emulsion has a mean droplet size in the range of between about 0.03 and 0.5 .mu.m, and preferably 0.05 and 0.2 .mu.m.
    Type: Grant
    Filed: April 29, 1996
    Date of Patent: October 5, 1999
    Assignees: Pharmos Corporation, The United States of America as represented by the Secretary of the Army
    Inventors: George H. Lowell, Shimon Amselem, Doron Friedman, Haim Aviv
  • Patent number: 5891469
    Abstract: Lipophilic active ingredients are co-melted with tocopherol polyethyleneglycol succinate (TPGS) and a dispersion adjuvant to obtain solid dry coprecipitate compositions suitable as an oral dosage form. The solid TPGS coprecipitates of lipophilic active ingredients show improved drug release in vitro and enhanced oral bioavailability in vivo.
    Type: Grant
    Filed: April 2, 1997
    Date of Patent: April 6, 1999
    Assignee: Pharmos Corporation
    Inventor: Shimon Amselem
  • Patent number: 5750142
    Abstract: The present invention relates to dry, stable compositions which can be reconstituted to form pharmaceutical or cosmetic emulsions, and to methods for making such compositions. An emulsion is formed from about 0.2 to 25 weight percent of a first component of an oil, about 0.1 to 5 weight percent of a second component of an emulsifier, about 0.25 to 25 weight percent of a cryoprotectant of an amino compound, such as one or more amino acids, peptides or protein hydrolysates, and an aqueous component, wherein the amino compound is present in an amount that is equal to or greater than that of the first component. Optionally, a co-emulsifier, a suspension agent, a preservative, an antioxidant and a drug can be added to these emulsions. Thereafter, the emulsion is lyophilized to form dry compositions that have from about 40 to about 90 weight percent of the amino compound; from about 0.1 to about 20 weight percent of the emulsifier; and from about 0.2 to about 40 weight percent of the oily component.
    Type: Grant
    Filed: April 11, 1997
    Date of Patent: May 12, 1998
    Assignee: Pharmos Corporation
    Inventors: Doron Friedman, Yanir Aldouby
  • Patent number: 5747061
    Abstract: The invention provides novel compositions of matter for delivering water-insoluble steroid drugs suitable for therapeutic use. The invention also provides stable aqueous suspensions of water-insoluble steroid drugs of particle sizes of .ltoreq.30 .mu.m which remain in such a state so as to allow for immediate suspension, when desired, even after extended periods of settling.
    Type: Grant
    Filed: July 29, 1996
    Date of Patent: May 5, 1998
    Assignee: Pharmos Corporation
    Inventors: Shimon Amselem, Doron Friedman
  • Patent number: 5716637
    Abstract: The present invention provides pharmaceutical vaccine compositions that are nanoemulsions of particles having a lipid core which is in a solid or liquid crystalline phase at 25.degree. C., and which is surrounded by at least one phospholipid bilayer for the parenteral, oral, intranasal, rectal, vaginal or topical delivery of both hydrophilic and lipophilic immunogens. The particles have a mean diameter in the range of 10 to 250 nm and the immunogen is incorporated therein, either intrinsically prior to the homogenization process or extrinsically thereafter.
    Type: Grant
    Filed: November 16, 1995
    Date of Patent: February 10, 1998
    Assignees: Pharmos Corporation, The United States of America as represented by the Secretary of the Army
    Inventors: Shimon Anselem, George H. Lowell, Haim Aviv, Doron Friedman
  • Patent number: 5662932
    Abstract: The present invention provides pharmaceutical compositions comprising nanoemulsions of particles comprising a lipid core which is in a solid or liquid crystalline phase at 25.degree. C., stabilized by at least one phospholipid envelope, for the parenteral, oral, intranasal, rectal, or topical delivery of both fat-soluble and water-soluble drugs. Particles have a mean diameter in the range of 10 to 250 nm. A wide variety of drugs and oxygen transporting perfluorocarbons may be encapsulated in the particles. In addition to drug delivery vehicles, the invention provides oxygen transporting blood substitutes, and nanoemulsions for extracorporeal maintenance of tissues prior to transplantation.
    Type: Grant
    Filed: August 27, 1996
    Date of Patent: September 2, 1997
    Assignee: Pharmos Corporation
    Inventors: Shimon Amselem, Doron Friedman
  • Patent number: 5650425
    Abstract: The present disclosure relates to compounds of the general formulae: ##STR1## wherein DRUG is a steroid agonist or antagonist, a mixed agonist-antagonist, or a partial agonist, and to the use of such compounds as anti-inflammatory and anti-tumor agents.
    Type: Grant
    Filed: April 4, 1994
    Date of Patent: July 22, 1997
    Assignee: Pharmos Corporation
    Inventors: Anat Biegnon, Marcus Brewster
  • Patent number: 5576016
    Abstract: The present invention provides pharmaceutical compositions comprising nanoemulsions of particles comprising a lipid core which is in a solid or liquid crystalline phase at 25.degree. C, stabilized by at least one phospholipid envelope, for the parenteral, oral, intranasal, rectal, or topical delivery of both fat-soluble and water-soluble drugs. Particles have a mean diameter in the range of 10 to 250 nm. A wide variety of drugs and oxygen transporting perfluorocarbons may be encapsulated in the particles. In addition to drug delivery vehicles, the invention provides oxygen transporting blood substitutes, and nanoemulsions for extracorporeal maintenance of tissues prior to transplantation.
    Type: Grant
    Filed: May 18, 1993
    Date of Patent: November 19, 1996
    Assignee: Pharmos Corporation
    Inventors: Shimon Amselem, Doron Friedman
  • Patent number: 5576311
    Abstract: The present invention relates to stable aqueous suspension of drugs suitable for therapeutic administration without requiring solubilization or complexation of those drugs. The suspensions are stabilized with cyclodextrin type suspending agents. Stabilized suspensions of corticosteroids which employ these suspending agents are useful for therapeutic treatment of the eye, ear, or nose.
    Type: Grant
    Filed: November 30, 1994
    Date of Patent: November 19, 1996
    Assignee: Pharmos Corporation
    Inventor: Yaacov J. Guy
  • Patent number: 5540930
    Abstract: The invention provides novel compositions of matter containing water-insoluble steroid drugs suitable for therapeutic use. The invention provides stable aqueous suspensions of water-insoluble steroid drugs of particle sizes of .ltoreq.15 .mu.m which remain in such a state so as to allow for immediate suspension, when desired, even after extended periods of settling.
    Type: Grant
    Filed: October 25, 1993
    Date of Patent: July 30, 1996
    Assignee: Pharmos Corporation
    Inventors: Yaacov J. Guy, Doron I. Friedman